These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 10494371)

  • 1. [Blood and plasma product safety from the viewpoint of public health officials].
    Willkommen H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):497-500. PubMed ID: 10494371
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blood and plasma product safety from viewpoint of the surgeon].
    Kussmann J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):495-7. PubMed ID: 10494370
    [No Abstract]   [Full Text] [Related]  

  • 3. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hemostasis and transfusion aspects of blood and plasma product safety].
    Seyfert UT; Mörsdorf S; Mertzlufft F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):488-92. PubMed ID: 10494368
    [No Abstract]   [Full Text] [Related]  

  • 5. [The anesthesiologic view of blood and plasma product safety].
    Mehrkens HH
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):492-5. PubMed ID: 10494369
    [No Abstract]   [Full Text] [Related]  

  • 6. [Physician liability and patient information related to blood and plasma product safety].
    Bock RW
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):501-3. PubMed ID: 10494372
    [No Abstract]   [Full Text] [Related]  

  • 7. [Virologic aspects of blood and plasma product safety].
    Gärtner BC; Mueller-Lantzsch N
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):486-8. PubMed ID: 10494367
    [No Abstract]   [Full Text] [Related]  

  • 8. Health outcomes research using large donor-recipient databases: a new frontier for assessing transfusion safety and contributing to public health.
    Busch M; Custer B
    Vox Sang; 2006 Nov; 91(4):282-4. PubMed ID: 17105602
    [No Abstract]   [Full Text] [Related]  

  • 9. [The clinical indications for and risks of fresh frozen plasma. A consensus conference. The Ministry of Health and Consumer Affairs].
    Angiologia; 1993; 45(5):184-7. PubMed ID: 8285367
    [No Abstract]   [Full Text] [Related]  

  • 10. Infectious disease in the blood supply and the public health response.
    Evatt B
    Semin Hematol; 2006 Apr; 43(2 Suppl 3):S4-9. PubMed ID: 16631825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current estimates of transfusion safety worldwide.
    Dodd RY
    Dev Biol (Basel); 2005; 120():3-10. PubMed ID: 16050149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The safety of blood and plasma products].
    Mertzlufft F; Wilhelm W
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 Aug; 34(8):485-6. PubMed ID: 10494366
    [No Abstract]   [Full Text] [Related]  

  • 13. [Understanding the role of the European public institutions in blood transfusion].
    Behr-Gross ME
    Transfus Clin Biol; 2009 May; 16(2):237-40. PubMed ID: 19443256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen reduction technologies: what are the concerns?
    AuBuchon JP
    Vox Sang; 2004 Jul; 87 Suppl 2():84-9. PubMed ID: 15209887
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on transfusion medicine.
    Shander A; Goodnough LT
    Pharmacotherapy; 2007 Sep; 27(9 Pt 2):57S-68S. PubMed ID: 17723109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Viral safety concept: application to blood and blood products].
    Trouvin JH
    Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Availability, safety and quality of blood for transfusion in the Americas.
    Cruz JR; Pérez-Rosales MD
    World Hosp Health Serv; 2005; 41(1):25, 27-31. PubMed ID: 15881823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment and cost-effectiveness/utility analysis.
    Busch M; Walderhaug M; Custer B; Allain JP; Reddy R; McDonough B
    Biologicals; 2009 Apr; 37(2):78-87. PubMed ID: 19243972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consideration in hemophilia therapy selection.
    Pipe S
    Semin Hematol; 2006 Apr; 43(2 Suppl 3):S23-7. PubMed ID: 16631824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transfusion safety and haemovigilance committees].
    Quaranta JF; Canivet N; Courbil R; Raucoules-Aimé M
    Transfus Clin Biol; 2007 May; 14(1):107-11. PubMed ID: 17513159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.